Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 8Sarcoma 7Sarcoma, Clear Cell 2Neurofibrosarcoma 2Nerve Sheath Neoplasms 2Neoplasm Metastasis 2Liposarcoma 2Kidney Neoplasms 2Histiocytoma, Angiomatoid Fibrous 2Granuloma, Plasma Cell 2Glioblastoma 2Fibrosarcoma 2Dermatofibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Vascular Neoplasms 1Solitary Fibrous Tumors 1Solid Neoplasm 1Smooth Muscle Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Refractory or Recurrent Solid Tumor 1Perivascular Epithelioid Cell Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Liposarcoma, Myxoid 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1

Interventions

pazopanib 1Geriatric Assessment 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Neoplasm × pazopanib × 1 year × Clear all
NCT01552356 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡